A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Recruiting · 30 sites across 20 states
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •Adults who are on stable maintenance hemodialysis (including hemodialysis, hemodiafiltration, or hemoadsorption) at least 3 times per week for at least 12 weeks before signing, and plan no change during the study
- •Adults with blood phosphate levels in the study-required range
- •Adults with dialysis adequacy meeting SpKt/V ≥ 1.20 at screening or documented ≥ 1.20 within 12 weeks before signing
- •If taking etelcalcetide, their dose is unchanged for at least 4 weeks before signing
- •Women who can become pregnant and non-sterile sexually active men agree to use highly effective contraception during the study and for 90 days after the last study dose
🚫 You may not be able to join if…
- •Pregnant or breastfeeding
- •Planning a living donor kidney transplant in the next 6 months, or planning a change in dialysis type (to peritoneal dialysis or home hemodialysis) during the study, or relocating to another dialysis center in the study
- •With a blood calcium or intact parathyroid hormone abnormality
- •With uncontrolled high blood pressure
- •Had certain recent serious events, such as hospitalization for cardiac or brain/circulation disease within 24 weeks, or acute hepatitis/significant chronic liver disease, or certain recent GI problems or stomach/intestinal surgery
- •If they have significant heart electrical rhythm/QT interval problems on an ECG, a serious active infection, recent cancer (with certain exceptions), are on certain strong/moderate CYP3A inhibitors recently, got another investigational treatment/device in the last 30 days, or have life expectancy less than 12 months
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults roughly 18–any age
- !Some conditions may not be a fit: High blood pressure
- !Not for people who are pregnant or breastfeeding
What to expect, step by step
- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
If you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
Has this treatment been tested before?
Yes. This treatment has already been through earlier human studies for safety before reaching this stage.
What you need to know before you apply
What is this study testing?+
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
Is it safe? Who makes sure of that?+
This is a mid-stage study (Phase 2), looking at safety and whether the treatment works. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
Do I have to stop taking my current medications?+
It depends on the study. Some let you stay on your current medications and some ask you to adjust them. Never stop a medication on your own — the study team will review everything with you first.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. Some studies also pay for your time; the coordinator can tell you if this one does. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Some requirements (like specific lab values or timing) are confirmed directly by the study team, not by us.
Source: ClinicalTrials.gov · NCT06712654 · Locations: Alabama · California · Colorado · Connecticut · Florida · Georgia · Michigan · Minnesota · Missouri · Nevada · New Mexico · New York · Ohio · Texas · Virginia · Beijing Municipality · Henan · Jiangsu · Shanghai Municipality · Sichuan